TABLE 1

Clinical characteristics of patient samples

SampleSex (M/F)Age (years)BMI (kg/m2)Fasting plasma glucose (mmol/l)Plasma glucose at 2 h OGTT (mmol/l)
Sibships
 Diabetes/severe IGT sib280/32965 ± 1029 ± 59.3 ± 3.314.3 ± 5.6
 NGT sib275/30562 ± 1026 ± 35.4 ± 0.46.0 ± 1.1
Scandinavia C/C
 Diabetes/severe IGT252/21960 ± 1028 ± 59.8 ± 3.415.0 ± 5.3
 NGT254/21760 ± 1027 ± 46.2 ± 1.86.8 ± 2.8
Canada C/C
 Diabetes70/5753 ± 829 ± 56.4 ± 1.812.8 ± 2.1
 NGT70/5752 ± 829 ± 45.1 ± 0.66.1 ± 1.1
Sweden C/C
 Diabetes/severe IGT267/24766 ± 1228 ± 48.5 ± 2.515.5 ± 4.0
 NGT267/24766 ± 1228 ± 44.8 ± 0.6ND
  • Data are presented as means ± SD. Plasma glucose was measured at baseline (fasting) and 2 h after an OGTT. IGT, impaired glucose tolerance; IFG, impaired fasting glucose; NGT, normal glucose tolerance; C/C, case/control; ND, not done.